aflibercept ophthalmic (Eylea)
Jump to navigation
Jump to search
Indications
- wet age-related macular degeneration
- diabetic macular edema
Contraindications
- active eye infection
- active ocular inflammation
Dosage
Solution: 40 mg/mL solution for intravitreal injection in a single-use vial
Adverse effects
- eye pain
- conjunctival hemorrhage
- vitreous floaters
- cataract
- increased intraocular pressure (may occur within 60 minutes)
- endophthalmitis & retinal detachments may occur following intravitreal injections
Mechanism of action
- recombinant fusion protein consisting of portions of human VEGF receptor 1 & VEGF receptor 2 extracellular domains fused to the Fc portion of human IgG1
- acts as a soluble decoy receptor that binds VEGF-A & PlGF
Notes
- in two randomized trials, involving 2400 patients, aflibercept was as effective as ranibizumab (Lucentis) in improving visual acuity
More general terms
References
- ↑ FDA NEWS RELEASE: Nov. 18, 2011 FDA approves Eylea for eye disorder in older people http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280601.htm
- ↑ The Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25692915 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1414264
Martin DF, Maguire MG. Treatment Choice for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. [Epub ahead of print] <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25692914 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1500351 - ↑ aflibercept (Eylea) prescribing information http://www.regeneron.com/docs/eylea-fpi.pdf